National Use of Thrombolysis with Alteplase for Acute Ischaemic Stroke via Telemedicine in Denmark: A Model of Budgetary Impact and Cost Effectiveness

Authors: Ehlers, Lars1; Müskens, Wilhelmina Maria2; Lotte Groth Jensen,1; Kjølby, Mette1; Andersen, Grethe3

Source: CNS Drugs, Volume 22, Number 1, 2008 , pp. 73-81(9)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Aim: The purpose of this analysis was to assess the budgetary impact and cost effectiveness of the national use of thrombolysis with alteplase (recombinant tissue plasminogen activator; rt-PA) for acute ischaemic stroke via telemedicine in Denmark.

Methods: Computations were based on a Danish health economic model of thrombolysis treatment of acute ischaemic stroke via telemedicine. Cost data for stroke units and satellite clinics were taken from the first practical experiences in Denmark with implementing thrombolysis via telemedical linkage to the Stroke Department at Aarhus University Hospital. Effectiveness data were taken from a published pooled analysis of results from randomized controlled trials of alteplase.

Results: The calculations showed that the additional total costs to the hospitals of implementing thrombolysis with alteplase for acute ischaemic stroke via telemedicine were approximately $US3.0 (range 2.0-5.8) million per year in the case of five centres and five satellite clinics, or $US3.6 (range 2.4-7.0) million per year based on seven centres and seven satellite clinics. The incremental cost-effectiveness ratio was calculated to be approximately $US50 000 when taking a short time perspective (1 year), but thrombolysis was dominant (both cheaper and more effective) after as little as 2 years and cost effectiveness improved over longer time scales.

Conclusion: The budgetary impact of using thrombolysis with alteplase for acute ischaemic stroke via telemedicine depends on the existing capacity and organizational conditions at the local hospitals. The health economic model computations suggest that the macroeconomic costs may balance with savings in care and rehabilitation after as little as 2 years, and that potentially large long-term savings are associated with thrombolysis with alteplase delivered by telemedicine, although the long-term calculations are uncertain.

Keywords: Alteplase; Cost effectiveness; Modelling; Stroke; Telemedicine; Thrombolytics

Document Type: Research article

Affiliations: 1: 1 HTA Unit, Aarhus University Hospital, Aarhus, Denmark 2: 2 Institute of Economics, Aarhus University, Aarhus, Denmark 3: 3 Department of Neurology, Aarhus University Hospital, Aarhus, Denmark

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A